This is a preview of subscription content, log in via an institution to check access.
Notes
Both studies were funded by Biogen Idec.
incremental cost-effectiveness ratio
References
Su W, et al. The Cost Effectiveness of Bg-12 (Dimethyl Fumarate) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND28, 2 Nov 2013.
Dorman E, et al. The Budget Impact of Introducing Bg-12 (Dimethyl Fumarate) for Treatment of Relapse-Remitting Multiple Sclerosis (Rrms) in Canada 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND14, 2 Nov 2013.
Rights and permissions
About this article
Cite this article
Economic impact of introducing dimethyl fumarate into Canada. PharmacoEcon Outcomes News 692, 4 (2013). https://doi.org/10.1007/s40274-013-0885-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0885-5